Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2025 10:12 ET | Source: Spherix Global Insights

Spherix Global Insights Expands Hematology Franchise to Include Oncology, Enhancing Advisory Services and Delivering Deeper Physician and Market Insights

EXTON, PA, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
September 26, 2025 05:29 ET | Source: Research and Markets

Anemia Treatment Market Analysis by Disease Type, Therapy Class, Route of Administration, Countries and Competitive Landscape 2025-2033

Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Anemia Treatment Market Report by Disease Type, Therapy Class, Route of Administration, Countries and Company Analysis, 2025-2033" report has been...
January 25, 2024 05:39 ET | Source: Research and Markets

Acquired Orphan Blood Disease Market Research Reveals Rapid Growth in Asia and Innovative Therapies

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Acquired Orphan Blood Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
June 06, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market - AbbVie, Gilead Sciences, Novartis, AstraZeneca, Sanofi, Incyte, Celgene, Fibrogen, Precigen

New Year, USA, June 06, 2023 (GLOBE NEWSWIRE) -- Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market - AbbVie, Gilead Sciences, Novartis,...
July 12, 2021 08:40 ET | Source: CMI

Myelodysplastic Syndrome Treatment Market in U.S., Europe, and China to Surpass US$ 3,404.1 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment market is estimated to be valued at US$ 2,042.6...
May 07, 2019 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update

Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...
November 05, 2018 13:00 ET | Source: Lixte Biotechnology Holdings, Inc.

FDA Approves Lixte Biotechnology’s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

EAST SETAUKET, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the FDA approved its IND to conduct a Phase 1b/2 trial of the safety and...
October 09, 2018 09:45 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

EAST SETAUKET, NY , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety...
August 21, 2018 09:45 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome

EAST SETAUKET, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement...
February 28, 2018 07:30 ET | Source: Actinium Pharmaceuticals

Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations

- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...